Summary:
- The U.S. Food and Drug Administration (FDA) has approved an updated prescribing information for Sarepta's drug Elevidys, which is used to treat a rare genetic disorder called Duchenne muscular dystrophy.
- The updated prescribing information includes new data on the safety and efficacy of Elevidys, which can help doctors and patients better understand how to use the medication effectively.
- This approval is important for patients with Duchenne muscular dystrophy, as it provides them with an approved treatment option that can help manage their condition and improve their quality of life.